R&D channel feed

Ace­lyrin crew be­hind first thy­roid eye dis­ease med­i­cine builds its po­ten­tial com­peti­tor, with ear­ly da­ta to boast

Last year

High­ly-await­ed PhI­II study of Gates-backed tu­ber­cu­lo­sis vac­cine un­der­way

Last year

Cri­net­ics re­ports sec­ond PhI­II win for acromegaly drug, eyes 2025 launch

Last year

With pos­i­tive PhI­II da­ta in hot flash­es, Bay­er is a step clos­er to chal­leng­ing Astel­las’ Veozah

Last year

No­vo Nordisk Foun­da­tion backs ef­fort to build su­per­com­put­er with Nvidia

Last year
AI

GSK’s new PhI­II da­ta sup­port bid for wider en­dome­tri­al can­cer la­bel for Jem­per­li

Last year
Pharma

Spruce Bio­sciences’ stock plum­mets in wake of PhI­Ib flop, biotech to cut staff

Last year
People

As­traZeneca eyes rare en­docrinol­o­gy mar­ket with $1.05B buy­out of Amolyt Phar­ma

Last year
Deals

Si­lence re­ports pos­i­tive PhII cho­les­terol drug da­ta, re­veals end to Mallinck­rodt al­liance

Last year
Deals

Io­n­is touts PhII MASH study da­ta that fea­ture its DGAT2 an­ti­sense in­hibitor

Last year

Sanofi to shut­ter ex-Kymab R&D fa­cil­i­ty in the UK

Last year
People

Cri­net­ics’ car­ci­noid syn­drome drug gears up for reg­is­tra­tional test af­ter PhII da­ta up­date

Last year

Topline Ad­cetris da­ta in blood can­cer could mean new in­di­ca­tion for Pfiz­er

Last year
Pharma

Roche is try­ing again and again in Alzheimer’s. This time, ear­ly da­ta are ‘worth watch­ing’

Last year

Bris­tol My­ers drops an­oth­er Cy­tomX pro­gram

Last year

The R&D 15: Top phar­ma play­ers shell out record $153B for re­search, and M&A is a prime fo­cus for all

Last year
Bioregnum
Special

As place­bo spoils PhI­II tri­al, Aca­dia does not in­tend to stage fur­ther Nu­plazid stud­ies in schiz­o­phre­nia

Last year

Lex­i­con gears up for an­oth­er shot in di­a­betes as path for­ward agreed with FDA

Last year
Pharma

#AAD24 roundup: Da­ta from Sanofi, Alu­mis, Gal­der­ma and more

Last year

Moon­Lake out­lines more da­ta in pso­ri­at­ic arthri­tis as it preps for piv­otal tri­als: #AAD24

Last year

As J&J's oral IL-23 takes on So­tyk­tu, one-year fol­low-up da­ta show dura­bil­i­ty: #AAD24

Last year

No­var­tis of­fers glimpse at BTK in­hibitor plans be­yond lead in­di­ca­tions: #AAD24

Last year

Akero ex­ec­u­tives point to ad­vanced fi­bro­sis pa­tients for MASH drug

Last year
Pharma

The FDA al­most nev­er pulls ful­ly-ap­proved drugs. Amy­lyx's ALS treat­ment might be the ex­cep­tion

Last year
FDA+
First page Previous page 51525354555657 Next page Last page
A service from the Financial Times